公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions | Chou Y.-H.; JA-DER LIANG ; Wang S.-Y.; SHIH-JER HSU ; Hu J.-T.; Yang S.-S.; Wang H.-K.; Lee T.-Y.; Tiu C.-M. | Journal of Medical Ultrasound | 17 | 15 | |
2006 | Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan | Lu S.-N.; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Wu J.-C.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; JIN-CHUAN SHEU ; DING-SHINN CHEN ; CHIEN-HUNG CHEN | International Journal of Cancer | 120 | 111 | |
2011 | Severe metabolic acidosis causes early lethality in NBC1 W516X knock-in mice as a model of human isolated proximal renal tubular acidosis | Lo Y.-F.; Yang S.-S.; Seki G.; Yamada H.; Horita S.; Yamazaki O.; Fujita T.; Usui T.; Tsai J.-D.; Yu I.-S.; SHU-WHA LIN ; Lin S.-H. | Kidney International | 47 | 43 | |
2022 | Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU ; Dai C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L.; Yu M.-L.; TACR investigators | Infectious Diseases and Therapy | 9 | 8 | |
2021 | Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan | CHEN-HUA LIU ; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU ; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; YU-JEN FANG ; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG ; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T. Y.; JIA-HORNG KAO | Hepatology International | 14 | 14 | |
2021 | Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis | CHEN-HUA LIU ; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU ; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; YU-JEN FANG ; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; JIA-HORNG KAO | Clinical and Molecular Hepatology | 8 | 8 | |
2020 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment | CHEN-HUA LIU ; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU ; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG ; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO | Gut | 26 | 27 | |
1998 | Somatosensory evoked potentials in subclinical portosystemic encephalopathy: A comparison with psychometric tests | Yang S.-S.; Wu C.-H.; Chiang T.-R.; DING-SHINN CHEN | Hepatology | 44 | 36 | |
2010 | SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction | Yang S.-S.; Lo Y.-F.; Wu C.-C.; SHU-WHA LIN ; Yeh C.-J.; Chu P.; Sytwu H.-K.; Uchida S.; Sasaki S.; Lin S.-H. | Journal of the American Society of Nephrology | 235 | 222 | |
2010 | Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan | Huang Y.-W.; Liao Y.-T.; Chen W.; CHI-LING CHEN ; Hu J.-T.; CHUN-JEN LIU ; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN ; Yang S.-S.; JIA-HORNG KAO | Genes and Immunity | 45 | 38 |